| scholarly article | Q13442814 |
| P356 | DOI | 10.2217/PGS.10.132 |
| P698 | PubMed publication ID | 21142914 |
| P50 | author | Lina Quteineh | Q47156267 |
| P2093 | author name string | Jörg König | |
| Martin F Fromm | |||
| Céline Verstuyft | |||
| Antoine Durrbach | |||
| Valérie Furlan | |||
| Bernard Charpentier | |||
| Sophie Ferlicot | |||
| Lina Quteineh | |||
| Laurent Becquemont | |||
| Alexia Letierce | |||
| Hugues Michelon | |||
| P2860 | cites work | The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients | Q46731220 |
| Clinical pharmacokinetics of mycophenolate mofetil | Q46787320 | ||
| Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation | Q46972643 | ||
| Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients | Q46973712 | ||
| Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients. | Q51913689 | ||
| Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele | Q24595480 | ||
| Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans | Q28209488 | ||
| IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients | Q28248331 | ||
| High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1) | Q28269517 | ||
| Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes | Q28354181 | ||
| SLCO1B1 variants and statin-induced myopathy--a genomewide study | Q29619028 | ||
| A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies. | Q33274432 | ||
| Mycophenolate mofetil and its mechanisms of action | Q33957177 | ||
| Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine | Q34338194 | ||
| Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients | Q34573738 | ||
| UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients | Q34947658 | ||
| UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients | Q34984788 | ||
| Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism | Q34993014 | ||
| Transporters and drug therapy: implications for drug disposition and disease | Q36253732 | ||
| Therapeutic drug monitoring of mycophenolate mofetil in transplantation | Q36455259 | ||
| Role of OATP transporters in the disposition of drugs | Q37074085 | ||
| Therapeutic monitoring of mycophenolate in transplantation: is it justified? | Q37411261 | ||
| The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. | Q39778798 | ||
| The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. | Q40171773 | ||
| Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid | Q40264387 | ||
| Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5. | Q40486663 | ||
| Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups | Q42551535 | ||
| Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil | Q43189802 | ||
| Influence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side effects in kidney transplant patients. | Q43718019 | ||
| Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. | Q44360338 | ||
| Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients. | Q46040442 | ||
| The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy | Q46055999 | ||
| Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients | Q46207616 | ||
| Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection | Q46246052 | ||
| Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial | Q46301570 | ||
| Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2. | Q46427135 | ||
| Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients | Q46434574 | ||
| The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice | Q46513372 | ||
| Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. | Q46542409 | ||
| A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil | Q46608340 | ||
| P433 | issue | 12 | |
| P304 | page(s) | 1703-1713 | |
| P577 | publication date | 2010-12-01 | |
| P1433 | published in | Pharmacogenomics | Q15724625 |
| P1476 | title | SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients | |
| P478 | volume | 11 |
| Q45345117 | Challenges and Opportunities with Predicting in Vivo Phase II Metabolism via Glucuronidation from in Vitro Data |
| Q38223136 | Do Asian renal transplant patients need another mycophenolate mofetil dose compared with Caucasian or African American patients? |
| Q38104742 | Genes and beans: pharmacogenomics of renal transplant |
| Q36183911 | Impact of Single Nucleotide Polymorphisms (SNPs) on Immunosuppressive Therapy in Lung Transplantation. |
| Q55715295 | Influence of uridine diphosphate-glucuronosyltransferases (1A9) polymorphisms on mycophenolic acid pharmacokinetics in patients with renal transplant. |
| Q38162034 | PharmGKB summary: mycophenolic acid pathway |
| Q38258677 | Pharmacogenetics and immunosuppressive drugs. |
| Q99630950 | Pharmacogenetics of immunosuppressant drugs: A new aspect for individualized therapy |
| Q38208983 | Pharmacology and toxicology of mycophenolate in organ transplant recipients: an update |
| Q26829263 | Plasma membrane transporters in modern liver pharmacology |
| Q51048064 | Population pharmacogenetic pharmacokinetic modeling for flip-flop phenomenon of enteric-coated mycophenolate sodium in kidney transplant recipients. |
| Q46498636 | Renal glucuronidation and multidrug resistance protein 2-/ multidrug resistance protein 4-mediated efflux of mycophenolic acid: interaction with cyclosporine and tacrolimus. |
| Q37933139 | The genetics of kidney transplantation |
| Q27009825 | The influence of UGT polymorphisms as biomarkers in solid organ transplantation |
| Q37862576 | Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions |
| Q45993586 | Uridine diphosphate glucuronosyltransferase 2B7 variant p.His268Tyr as a predictor of kidney allograft early acute rejection. |
Search more.